Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:38 2024-04-18 am EDT			5-day change	1st Jan Change
862.7 ^DKK	-0.99%		-0.76%	+23.58%

Apr. 18	India's Biocon developing its own version of Wegovy, clinical trial likely next year	RE
Apr. 15	More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm	RE

Novo Nordisk A/S : - Saxenda demonstrated improvements in BMI and body weight in adolescents with obesity

April 01, 2020 at 06:26 am EDT

Bagsvaerd - Novo Nordisk today announced that a peer-reviewed journal published the results of a phase 3 trial evaluating the investigational use of Saxenda (liraglutide 3.0 mg) in adolescents (aged 12-

Latest news about Novo Nordisk A/S

India's Biocon developing its own version of Wegovy, clinical trial likely next year	Apr. 18	RE
More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm	Apr. 15	RE
Biophytis: patent application filed in the field of obesity	Apr. 15	CF
Health Care Falls as Risk Aversion Weighs on Obesity Drug Makers -- Health Care Roundup	Apr. 12	DJ
European Equities Close Mixed in Friday Trading; German Inflation Slows, UK GDP Rises	Apr. 12	MT
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says	Apr. 12	DJ
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Apr. 12	MT
Novo Nordisk's Wegovy, Ozempic Have No Added Suicide Risk, EU Says	Apr. 12	MT
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs	Apr. 12	MT
Novo Nordisk's Wegovy, Ozempic Have No Added Suicide Risk, EU Says	Apr. 12	MT
European Medicines Agency Finds No Increased Suicide Risk Link to Novo Nordisk's Wegovy, Ozempic	Apr. 12	MT
BMO Capital Starts Novo Nordisk With Outperform Rating, $163 Price Target	Apr. 12	MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts	Apr. 12	RE
Gerresheimer shares down on outlook, but key contracts confirmed	Apr. 11	RE
Gerresheimer supplies 'key players' in GLP-1 drugs market, CEO says	Apr. 11	RE
Gerresheimer expects sales boost from burgeoning obesity drugs sector	Apr. 11	RE
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update	Apr. 10	DJ
Ginkgo Bioworks Expands Research Partnership With Novo Nordisk	Apr. 10	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
Biophytis launches clinical study in obesity	Apr. 09	CF
Novo Nordisk Parent Resubmits Application Seeking US Antirust Nod for Catalent Deal	Apr. 09	MT
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 08	MT
Sector Update: Health Care Stocks Softer Monday Afternoon	Apr. 08	MT
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	Apr. 08	MT
Novo Nordisk Parent Resubmits US Antirust Application for Catalent Acquisition	Apr. 08	MT

Chart Novo Nordisk A/S

Duration

Period

More charts

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

2024-05-02 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVO NORDISK : Novo’s bag is full of pearls!

March 15, 2024 at 05:22 am EDT

Kasim Kutay, CEO of Novo Holdings: Catalent purchase marks new era of acquisitions

March 12, 2024 at 07:21 am EDT

Novo Nordisk doesn't disappoint

January 31, 2024 at 10:48 am EST

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

862.7 DKK

Average target price

904.2 DKK

Spread / Average Target

+4.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+23.58%	554B
ELI LILLY AND COMPANY	+27.97%	676B
JOHNSON & JOHNSON	-7.02%	349B
MERCK & CO., INC.	+14.85%	318B
ABBVIE INC.	+6.25%	291B
ASTRAZENECA PLC	+2.96%	210B
NOVARTIS AG	-0.41%	204B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-11.81%	144B
AMGEN INC.	-8.80%	142B

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Novo Nordisk A/S : - Saxenda demonstrated improvements in BMI and body weight in adolescents with obesity

EPS Revisions